Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Prostatic Neoplasms 13Breast Neoplasms 9Neoplasms 7Lung Neoplasms 7Lymphoma 5Pancreatic Neoplasms 4Melanoma 4Lymphoma, Non-Hodgkin 4Head and Neck Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Hepatocellular 4Urinary Bladder Neoplasms 3Rectal Neoplasms 3Brain Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neuroendocrine Tumors 2Neoplasms, Plasma Cell 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Multiple Myeloma 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, Extranodal NK-T-Cell 2Leukemia 2Hodgkin Disease 2Esophageal Neoplasms 2

Interventions

Cyclophosphamide 87fludarabine 74Tacrolimus 45fludarabine phosphate 44Mycophenolic Acid 42Whole-Body Irradiation 41Busulfan 35Melphalan 31Antilymphocyte Serum 24thymoglobulin 22Methotrexate 22Rituximab 21venetoclax 20Standard of Care 20Sirolimus 20Azacitidine 20Thiotepa 19Stem Cell Transplantation 18Granulocyte Colony-Stimulating Factor 18Practice Guidelines as Topic 16Cytarabine 16Nivolumab 15Filgrastim 15Dexamethasone 14Cyclosporine 13Bortezomib 13Mesna 12Peripheral Blood Stem Cell Transplantation 11trametinib 10Specimen Handling 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hematologic Neoplasms × Positron-Emission Tomography × Clear all
NCT05371054 2026-02-23

Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
8 enrolled 20 charts
LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Non-Hodgkin, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡